Prilosec
This article was originally published in The Tan Sheet
Executive Summary
Manhattan federal judge rejects AstraZeneca assertion generic omeprazole would infringe patent for active metabolites of Prilosec. '499 patent encompasses synthetic sulphenamides only, not those produced through in vivo conversion of omeprazole, court concludes May 29. Rulings on three antibiotic-related Prilosec patents expected in August in AstraZeneca's ongoing litigation against four generic firms. Basic omeprazole patent expires in October. Last year, two FDA advisory committees voted against OTC episodic heartburn relief indication for Prilosec but left open possibility of a chronic heartburn indication
You may also be interested in...
Prilosec inquiry
Stop Patient Abuse Now! (SPAN) coalition is calling on FTC and New York AG's office to launch an inquiry into whether Prilosec manufacturer AstraZeneca engaged in fraud. SPAN alleges AstraZeneca may have infringed on prior art by submitting a patent already held by a Korean firm to block generic competition in U.S. Group also claims New York consumers and taxpayers could save as much as $15 mil. a month if generic versions of the drug were approved. AstraZeneca, which along with P&G is seeking to switch the proton pump inhibitor OTC, is involved in ongoing patent litigation related to the drug (1"The Tan Sheet" July 9, 2001, In Brief and 2June 4, 2001, In Brief)...
Prilosec inquiry
Stop Patient Abuse Now! (SPAN) coalition is calling on FTC and New York AG's office to launch an inquiry into whether Prilosec manufacturer AstraZeneca engaged in fraud. SPAN alleges AstraZeneca may have infringed on prior art by submitting a patent already held by a Korean firm to block generic competition in U.S. Group also claims New York consumers and taxpayers could save as much as $15 mil. a month if generic versions of the drug were approved. AstraZeneca, which along with P&G is seeking to switch the proton pump inhibitor OTC, is involved in ongoing patent litigation related to the drug (1"The Tan Sheet" July 9, 2001, In Brief and 2June 4, 2001, In Brief)...
Prilosec inquiry
Stop Patient Abuse Now! (SPAN) coalition is calling on FTC and New York AG's office to launch an inquiry into whether Prilosec manufacturer AstraZeneca engaged in fraud. SPAN alleges AstraZeneca may have infringed on prior art by submitting a patent already held by a Korean firm to block generic competition in U.S. Group also claims New York consumers and taxpayers could save as much as $15 mil. a month if generic versions of the drug were approved. AstraZeneca, which along with P&G is seeking to switch the proton pump inhibitor OTC, is involved in ongoing patent litigation related to the drug (1"The Tan Sheet" July 9, 2001, In Brief and 2June 4, 2001, In Brief)...